Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Paradigm Biopharmaceuticals’ (ASX:PAR) support from the US Food and Drug Administration, paving the way for a pivotal clinical drug trial. 

Looking for alternative and equally innovative avenues to address unmet needs, Paradigm identified the potential of pentosan polysulfate sodium.

Tune in to get the latest.

 

While Paradigm Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.

Read MoreBiotechHealth

Featured Companies

You might be interested in